(Q35226240)

7 August 2017

1 reference

title

Clinical experience with topotecan in relapsed ovarian cancer (English)

1 reference

7 August 2017

1 reference

Thomas J Herzog

1

1 reference

PubMed ID

13129489

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

90

1 reference

7 August 2017

3 Pt 2

1 reference

7 August 2017

S3-7

1 reference

A comprehensive look at the early detection of ovarian cancer

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Screening for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Use of proteomic patterns in serum to identify ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Weekly topotecan in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Optimal sequencing in the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900467-0

7 January 2021

10.1016/S0090-8258(03)00467-0

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

13129489